Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2008
11/20/2008US20080286350 Formulation of Multivalent Antibody Constructs and Use of Same for Cancer Therapy
11/20/2008US20080286337 Method of treating a disease in an eye using a scleral lens
11/20/2008US20080286330 Treat Alzheimer's; chronic delivery of an anti-A beta antibody to central nervous system by infusion device; stop deposition of, remove cerebral vascular amyloid plaque
11/20/2008US20080286315 Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
11/20/2008US20080286314 Dendritic cells loaded with heat shocked melanoma cell bodies
11/20/2008US20080286313 Peptide Vaccines for the Treatment of Cancers
11/20/2008US20080286312 Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
11/20/2008US20080286311 providing a wild-type protein allergen, splicing it into two parts that have a reduced allergenic activity or lacking allergenic activity and rejoining the two fragments in inverse orientation; allergy immunotherapy; low risk for anaphylactic shock; preparation of antiallergens
11/20/2008US20080286310 Sequences coding Shiga toxin are deleted and those encoding bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor are mutated to inactivate them
11/20/2008US20080286309 Portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection; genetic engineering; Porcine erysipelas; high purity
11/20/2008US20080286308 Respiratory disease in cattle; immunostimulants; bioassay
11/20/2008US20080286307 Two-Step Temperature Profile for the Propagation of Viruses
11/20/2008US20080286306 Plasmid DNA or viral vector vaccine including components from different clades of Env and Gag-Pol-Nef from a single clade; multiclade HIV envelope immunogen
11/20/2008US20080286305 Transgenic lymphocytic cells comprising nucleotide sequences which code tumor, bacterial and or viral antigens for use as tools in delivering vaccines to disease bearing tissues; drug delivery
11/20/2008US20080286304 Use of pre-viral DNA replication enveloped particles (PREPS) and/or L-particles for manufacture of a medicament for regulating leukocyte function; Cytotoxic T Lymphocytes
11/20/2008US20080286303 Mutant Hin47 protein with decreased protease activity, and a high molecular weight protein of a strain of non-typeable Haemophilus influenzae; may be combined with diphtheria or tetanus toxoids, pertussis antigens or non-virulent poliovirus; immunization; otitis media
11/20/2008US20080286302 Two live mutant viruses of the same family containing a mutation in the viral genome at the same genomic site so the mutant viruses cannot recombine with each other to eliminate the mutations; Bovine viral diarrhea virus ; veterinary medicine
11/20/2008US20080286300 Improved quality control for conjugate vaccines; faster and more reproducible separation; analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units; meningoccocus; analyses sialic acid, glucose and galactose content
11/20/2008US20080286297 Chimeric Carrier Molecules for the Production of Mucosal Vaccines
11/20/2008US20080286296 Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions
11/20/2008US20080286295 Use of recombinant antigens to determine the immune status of an animal
11/20/2008US20080286294 Nodavirus-Vlp Immunization Composition
11/20/2008US20080286293 Promiscuous pap cd4 t cell epitopes
11/20/2008US20080286292 Molecular vaccine linking intercellular spreading protein to an antigen
11/20/2008US20080286291 Betulinol Derivatives as Anti-Hiv Agents
11/20/2008US20080286290 Anti-Cd14 Antibody Fusion Protein
11/20/2008US20080286289 Use of B Cell Expansion Agents in Generating Antibodies
11/20/2008US20080286288 Vascular endothelial growth factor 2
11/20/2008US20080286287 Methods and Agents for Modulating Cellular Activity
11/20/2008US20080286286 Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
11/20/2008US20080286285 Methods for Treating Vascular Disease
11/20/2008US20080286284 Compositions of PSMA antibodies
11/20/2008US20080286283 Treatment of cancer with antibodies to costimulating polypeptide of T cells
11/20/2008US20080286282 Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
11/20/2008US20080286281 Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation
11/20/2008US20080286280 Stable Lyophilized Pharmaceutical Preparations of Monoclonal or polyclonal antibodies
11/20/2008US20080286279 Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
11/20/2008US20080286278 Process for in vivo treatment of specific biological targets in bodily fluids
11/20/2008US20080286277 Monoclonal antibody comprising specificity determining residues for targeting tumor cells for destruction
11/20/2008US20080286276 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
11/20/2008US20080286275 Antigen Binding Proteins Directed Against Scavenger Receptor B1 that Inhibit Hcv Replication
11/20/2008US20080286274 Vector for Efficient Selection and/or Maturation of an Antibody and Uses Thereof
11/20/2008US20080286273 Knowledge-Based Proliferation Signatures and Methods of Use
11/20/2008US20080286272 EphA3 Antibodies for the Treatment of Solid Tumors
11/20/2008US20080286271 Methods and Compositions for Modulating Tweak and Fn14 Activity
11/20/2008US20080286270 Stabilized liquid anti-RSV antibody formulations
11/20/2008US20080286269 Anti-alpha(v)beta(6) antibodies and uses thereof
11/20/2008US20080286268 Processed ecm materials with enhanced component profiles
11/20/2008US20080286267 Methods for treating nervous system inquiry and disease
11/20/2008US20080286266 Novel Use of Il-1Beta Compounds
11/20/2008US20080286265 Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators
11/20/2008US20080286264 Modulation of Muc1 Activity
11/20/2008US20080286263 Diagnosis Of Neurodegenerative Diseases
11/20/2008US20080286262 Photosensitizers for Photodynamic Therapy at Infrared Excitation
11/20/2008US20080286261 Methods of modulating hair growth
11/20/2008US20080286199 Methods of Detecting Ovarian Cancer
11/20/2008US20080286198 Novel anti-IGF-IR antibodies and uses thereof
11/20/2008US20080286197 Antibody recognizing misfolded proteins that can be assigned specifically to one of the diseases
11/20/2008US20080286178 Microbial deactivation apparatus having integrated ultrasonic drying system
11/20/2008DE102007023183A1 Verwendung von Autoantikörpern gegen CD28 als prognostischer Marker beim malignen Melanom Use of auto-antibodies to CD28 as a prognostic marker in malignant melanoma
11/20/2008DE102007022669A1 Verwendung von CRMP1 als Marker für chronisch psychiatrische Erkrankungen Use of CRMP1 as a marker for chronic psychiatric disorders
11/20/2008CA2687403A1 Carbohydrate-containing pan cancer marker
11/20/2008CA2687301A1 Synthetic herpes simplex viruses type-1 for treatment of cancers
11/20/2008CA2687266A1 Means and methods for enhancing differentiation of haematopoietic progenitor cells
11/20/2008CA2687146A1 Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (pcv2) infection
11/20/2008CA2687115A1 Treatment and prevention of influenza
11/20/2008CA2683568A1 Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
11/20/2008CA2682700A1 Composition containing hcmv particles
11/20/2008CA2680344A1 Humaneered anti-factor b antibody
11/20/2008CA2676149A1 Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
11/20/2008CA2673535A1 Modified polymerases and attenuated viruses and methods of use thereof
11/20/2008CA2673355A1 Antigenicity of infectious pancreatic necrosis virus vp2 sub-viral particles expressed in yeast
11/20/2008CA2670315A1 Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
11/19/2008EP1992696A1 Circovirus sequences associated with porcine wasting disease (PWD)
11/19/2008EP1992695A2 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
11/19/2008EP1992644A1 Antibodies against CCR4 and its fragments
11/19/2008EP1992643A2 Compositions and methods for the diagnosis and treatment of tumor
11/19/2008EP1992640A1 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
11/19/2008EP1992639A1 Peptide vaccine for inducing production of anti-amyloid- -peptide antibody
11/19/2008EP1992636A2 Process for correction of a disulfide misfold in Fc molecules
11/19/2008EP1992359A1 Neurotropic virus transport
11/19/2008EP1992358A1 Aids vaccine based on replicative vaccinia virus vector
11/19/2008EP1992357A1 Botulinum toxin treatments of neurological and neuropsychiatric disorders
11/19/2008EP1991874A2 Diagnostic kits to detect sp22 and sp22 antibodies
11/19/2008EP1991710A2 Method for screening hiv drug sensitivity
11/19/2008EP1991709A2 Pseudoinfectious flavivirus and uses thereof
11/19/2008EP1991672A2 Methods and compositions for diagnosis and immunotherapy of pollen allergy
11/19/2008EP1991583A1 Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
11/19/2008EP1991582A2 Antibodies against secreted frizzled related protein-4 (sfrp-4)
11/19/2008EP1991565A2 Shiga toxoid chimeric proteins
11/19/2008EP1991564A2 Virosome-like vesicles comprising gp41-derived antigens
11/19/2008EP1991563A2 Peptide sequences and compositions
11/19/2008EP1991274A1 Method of treatment, prophylaxis and diagnosis of pathologies of the bone
11/19/2008EP1991268A2 Angiogenesis pathway gene polymorphisms for therapy selection
11/19/2008EP1991267A2 Methods of treating inflammatory and autoimmune diseases with natalizumab
11/19/2008EP1991266A2 Novel glycolipid adjuvant compositions
11/19/2008EP1991264A2 Compositions that include hemagglutinin, methods of making and methods of use thereof
11/19/2008EP1991263A2 Engineered listeria and methods of use thereof
11/19/2008EP1991262A2 Mycoplasma hyopneumoniae vaccine
11/19/2008EP1991261A2 Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
1 ... 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 ... 1823